The propensity of plaque to disrupt is a major determinant of future @entity63 events. Although they are distinct from one another, the @entity731 and thrombotic processes appear to be interdependent and may be integrated under the term "atherothrombosis." It is now clear that plaque composition, rather than the percent @entity850 , is a major determinant of plaque vulnerability. Plaque disruption seems to depend on both passive and active phenomena and is not purely mechanical. @entity32 (activation of monocytes/macrophages) is a major determinant of both plaque vulnerability and thrombogenicity as they relate to @entity952 . In one-third of @entity1187 , there is, however, no @entity952 but only superficial erosion of a markedly stenotic, fibrotic plaque. In these cases, @entity715 formation may be exacerbated by a hyperthrombogenic state present in @entity1 with certain systemic risk factors. The endothelium plays a pivotal role in vascular homeostasis and hemostasis. This dynamic organ regulates blood thrombogenicity as well as contractile, secretory, and mitogenic activities in the vessel wall. Some classic risk factors induce @entity409 by reducing the bioavailability of @entity842 , increasing tissue @entity2232 , and activating pro-inflammatory signaling pathways. @entity455 , which is the maintenance of blood fluidity and vascular integrity, is achieved by counter-balancing the intrinsic clotting tendency of blood. As a consequence of the central role of endothelial cells in hemostatic control, a dysfunctional endothelium will generate a pro-thrombotic environment favoring development of @entity731 and @entity715 .

Pathogenetic concepts of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['Inflammation'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndromes'] @entity455 :: ('MESH:D014652', 'Disease') :: ['Vascular hemostasis'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity2232 :: ('1906', 'Gene') :: ['endothelin-1'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity952 :: ('MESH:D019958', 'Disease') :: ['plaque disruption'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic', 'atherosclerotic lesions'] @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic complications', 'thrombus']
@entity1187 :: (MESH:D054058,Disease) :: ['acute coronary syndromes']
